...to announce its first program soon. Butts was a co-founder and COO at anticonvulsive company Neuronex Inc....

...or from previously approved products. Acorda gained the product through its December 2012 acquisition of Neuronex Inc....

...or from previously approved products. Acorda gained rights to Plumiaz through its 2012 acquisition of Neuronex Inc....

...gained the proprietary formulation of diazepam as a nasal spray through its 2012 acquisition of Neuronex Inc....

...literature or from previously approved products. Acorda gained the product through its 2012 acquisition of Neuronex Inc....

...be included in the NDA submission. Acorda gained the product through its 2012 acquisition of Neuronex Inc....

...Acorda completed its acquisition of Neuronex, which is developing a nasal spray formulation of diazepam for...
...a closing payment of $6.8 million. Acorda made an initial payment of $2 million to Neuronex...
...and an additional payment of $1.5 million to fund R&D activities prior to deal close. Neuronex...

...January 2011 by the management team behind North Carolina-based neurology companies Addrenex Pharmaceuticals Inc. and Neuronex Inc....
...Khayrallah, and President and COO Stephen Butts, both of whom were executives at Addrenex and Neuronex...
...& Co. Ltd. (Tokyo:4507; Osaka:4507) acquired Addrenex, while Acorda Therapeutics Inc. (NASDAQ:ACOR) agreed to acquire Neuronex...

...the product for acute repetitive seizures in China in 2013 and in Korea in 2015. Neuronex Inc....

...Acorda agreed to acquire Neuronex, which is developing a nasal spray formulation of diazepam for epilepsy...
...spray formulation of diazepam for epilepsy. Acorda made an initial payment of $2 million to Neuronex...
...deal. Acorda has the option to complete the acquisition for an additional $6.8 million after Neuronex's...